ImmunoTherapyNews.net

Cancer immunotherapy

Xagena Mappa
Medical Meeting
XagenaNewsletter
Onco News

Recently, it was reported a 56% objective response rate in patients with advanced Merkel cell carcinoma ( MCC ) receiving Pembrolizumab ( Keytruda ). However, a biomarker predicting clinical respons ...


Merkel cell carcinoma ( MCC ) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease ( mMCC ). In an initial analysis from JAVELIN Mer ...


The purpose of the study was to describe the prevalence, clinical presentation, and management of rheumatic immune‐related adverse effects ( Rh‐irAEs ) from immune checkpoint inhibitor ( ICI ) therapy ...


Cancer immunotherapy with checkpoint inhibitors ( CPIs ) is associated with frequent immune-related adverse events ( irAEs ) and is often not recommended for patients with concomitant autoimmune disea ...


Programmed cell death protein ligand-1 ( PD-L1 ) inhibitors are novel anti-cancer therapies but are associated with potentially therapy limiting immune-related adverse effects ( IRAEs ). The purpos ...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion, recommending a marketing authorisation of Imfinzi ( Durvalumab ) fo ...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In the setting of cancer, IDO pathway-mediated immune ...


Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of ...


Data from the GOG-0265 study were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. GOG-0265 is a single arm, phase 2 trial evaluating Axalimogene filolisbac for ...


Strategies to help improve the efficacy of the immune system against cancer represent an important innovation, with recent attention having focused on anti-programmed death (PD)-1 / PD-ligand 1 (L1) m ...


Avelumab is a fully human anti-PD-L1 IgG1 antibody being investigated in multiple clinical trials. Safety and clinical activity of Avelumab as a second-line therapy in patients with metastatic uro ...


Outcomes are poor for patients with recurrent / metastatic squamous cell carcinoma of the head and neck ( SCCHN ), and new treatments are needed. An ongoing phase I/II, multicenter, open-label study ...


Brain metastases develop in 40% of metastatic melanoma patients. Untreated brain metastases exclude from most clinical trials. In prior trials, treatment of metastatic melanoma with Pembrolizumab ( Ke ...


Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma and in other cancers. Factors predictive of response remain vaguely defined. Researchers have reported on clinical ch ...


Pembrolizumab ( Keytruda ) is a potent, highly selective humanized monoclonal antibody against PD-1 designed to block interaction with PD-L1 and PD-L2 and remove the inhibition of T-cell activation ag ...